International Academic Achievements and Awards

   Triple-negative breast cancer (TNBC) represents one of the most aggressive and treatment-resistant subtypes of breast cancer, lacking the expression of estrogen receptors, progesterone receptors, and HER2 amplification. This molecular profile limits targeted therapy options and leaves chemotherapy and radiotherapy as the primary modalities for treatment. Recent research has illuminated a promising therapeutic avenue centered on  Artemis (DCLRE1C)  — a DNA repair enzyme pivotal for the repair of double-strand breaks (DSBs). The study titled  “Artemis (DCLRE1C) Acts as a Target to Enhance Radiotherapy Response in Triple-Negative Breast Cancer”  reveals groundbreaking evidence that inhibiting Artemis sensitizes TNBC cells to radiotherapy, amplifying its cytotoxic efficacy. 🔬✨  Academic Achievements At the cellular level, Artemis (DCLRE1C) functions as a  key component of the non-homologous end joining (NHEJ)  pathway, which repairs radiation...